Preliminary data from the trial showed that TNX-102 SL did not achieve the primary goal of reducing pain in fibromyalgia patients by at least 30 percent over a three-month period.
Since the drug demonstrated a stronger effect on PTSD patients, the company will now shift their full attention to a late-stage study for this indication.
“We decided that PTSD was the better choice for us,” Seth Lederman, CEO of Tonix, told Reuters. He believes the treatment has potential to achieve a breakthrough therapy status as the Food and Drug Administration has not approved a new PTSD treatment in 15 years.
The company plans to conduct a late-stage study on TNX-102 SL’s ability to treat PTSD in the first quarter of 2017.
More articles on supply chain:
Study prompts formal recommendations for insulin injections
Merck halts development of osteoporosis drug in light of stroke risk
Clinton’s plan to address price hikes on long-standing drugs: 4 points
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
